Floatz logo

Eloxatin

Undifferentiated Pancreatic Carcinoma

Case Comprehensive Cancer CenterPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Undifferentiated Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Case Comprehensive Cancer Center
Phase 2CCC
Irinotecan
Case Comprehensive Cancer Center
Phase 2CCC

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
colon adenocarcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal neoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →